Peptide directory

Find a peptide

Public profiles inside a larger governed registry

Search by peptide name, brand, or research code. Open a full evidence profile or the published sources available for a record still in development. Source publication does not mean a completed scientific appraisal.

The registry is an expanding catalog, not a complete list of every peptide. A missing public result does not mean no research exists.

There are 51 full evidence profiles. "Complete profiles" is a stricter subset of them (12): Full profiles that pass every blocking completion check (published sources, a documented review of a source, chemistry, two regulatory records, linked conclusions and the narrative sections). A full evidence profile that is not yet complete has simply not passed every one of those checks.

Published profiles

Search profiles and sources

Compare peptides side by side →
Refine by category
Category

34 peptide records (34 full evidence profiles, 0 source-only records)

  • PTHrP analog

    Abaloparatide

    Peptide analog

    Emerging

    Abaloparatide is a synthetic 34-residue analog of human parathyroid hormone-related protein, PTHrP(1–34), designed to activate the parathyroid hormone type 1 receptor. Intermittent subcutaneous exposure produces an osteoanabolic response by stimulating osteoblast activity and increasing bone formation. The molecule contains an α-aminoisobutyric-acid substitution and is distinct from endogenous PTHrP and from teriparatide. Regulatory authorization is product- and jurisdiction-specific: the FDA-approved TYMLOS label covers defined high-fracture-risk postmenopausal women and men, while the EMA-authorized ELADYNOS indication is for postmenopausal women at increased fracture risk.

    • 25 published sources
    • 23 with study appraisals
    • no linked conclusions
    • Documented human review
    Evidence and record details

    Evidence integrity map

    Human 1Preclinical 0Durable IDs 6Open signals 2
    Publication state
    Published profile
    Verified source records
    25 source records verified
    Chemistry record
    Chemistry record on file
    Regulatory entries
    2 published regulatory entries
    Research questions
    4 open research questions
    Evidence review date
    Documented human review recorded Sep 20, 2026

    Source verification checks records; it does not itself approve scientific conclusions.

  • Growth-hormone fragment analog

    AOD-9604

    Developing

    AOD-9604 is a modified peptide derived from the C-terminal region of human growth hormone and was developed to investigate lipolytic and anti-obesity effects while attempting to avoid the broader growth-promoting actions of full-length growth hormone.

    • 25 published sources
    • 25 with study appraisals
    • 25 linked conclusions
    • Complete profile
    Evidence and record details

    Evidence integrity map

    Human 4Preclinical 11Durable IDs 23Open signals 4
    Publication state
    Published profile
    Verified source records
    25 source records verified
    Chemistry record
    Chemistry record on file
    Regulatory entries
    2 published regulatory entries
    Research questions
    22 open research questions
    Evidence review date
    No documented human review recorded

    Source verification checks records; it does not itself approve scientific conclusions.

  • Direct thrombin inhibitor peptide

    Bivalirudin

    Synthetic peptide

    Developing

    Bivalirudin is a synthetic 20-residue peptide anticoagulant derived conceptually from the thrombin-binding properties of hirudin. Its N-terminal D-phenylalanine-containing sequence binds the catalytic site of thrombin while a C-terminal region engages thrombin’s fibrin-recognition exosite; thrombin can subsequently cleave the molecule, contributing to reversible inhibition. It acts directly on circulating and clot-bound thrombin without requiring antithrombin. The molecule is established in percutaneous coronary intervention, while use in extracorporeal membrane oxygenation, cardiopulmonary bypass, pediatric procedures, and other settings has a different and often off-label evidence and regulatory context.

    • 25 published sources
    • 24 with study appraisals
    • no linked conclusions
    Evidence and record details

    Evidence integrity map

    Human 1Preclinical 1Durable IDs 7Open signals 1
    Publication state
    Published profile
    Verified source records
    25 source records verified
    Chemistry record
    Chemistry record on file
    Regulatory entries
    2 published regulatory entries
    Research questions
    No open questions documented
    Evidence review date
    No documented human review recorded

    Source verification checks records; it does not itself approve scientific conclusions.

  • Synthetic research peptide

    BPC-157

    Developing

    BPC-157 is a synthetic 15-amino-acid peptide derived from a sequence associated with gastric proteins. Experimental studies report effects on angiogenesis, nitric-oxide signaling, inflammatory pathways, and tissue repair, but the proposed mechanisms are not established as therapeutic mechanisms in humans.

    • 25 published sources
    • 25 with study appraisals
    • 25 linked conclusions
    • Complete profile
    Evidence and record details

    Evidence integrity map

    Human 4Preclinical 16Durable IDs 26Open signals 3
    Publication state
    Published profile
    Verified source records
    25 source records verified
    Chemistry record
    Chemistry record on file
    Regulatory entries
    2 published regulatory entries
    Research questions
    23 open research questions
    Evidence review date
    No documented human review recorded

    Source verification checks records; it does not itself approve scientific conclusions.

  • Oxytocin analog

    Carbetocin

    Peptide analog

    Developing

    Carbetocin is a synthetic long-acting oxytocin analog and agonist at the oxytocin receptor. Structural changes—including a thioether bridge and O-methyltyrosine substitution—slow enzymatic degradation relative to oxytocin. In obstetric use it stimulates uterine smooth-muscle contraction after delivery; authorization, route, dose, and eligible population remain product- and jurisdiction-specific. Intranasal developmental research in Prader–Willi syndrome is a distinct investigational context and is not evidence of an obstetric product’s authorization for that use.

    • 25 published sources
    • 25 with study appraisals
    • no linked conclusions
    Evidence and record details

    Evidence integrity map

    Human 1Preclinical 0Durable IDs 7Open signals 2
    Publication state
    Published profile
    Verified source records
    25 source records verified
    Chemistry record
    Chemistry record on file
    Regulatory entries
    2 published regulatory entries
    Research questions
    No open questions documented
    Evidence review date
    No documented human review recorded

    Source verification checks records; it does not itself approve scientific conclusions.

  • Long-acting GHRH analog

    CJC-1295

    Developing

    CJC-1295 is a modified growth-hormone-releasing hormone analog designed to resist enzymatic degradation and, in its drug-affinity-complex form, bind circulating albumin. Early studies show prolonged stimulation of growth hormone and IGF-1, but biomarker elevation is not equivalent to demonstrated clinical benefit.

    • 25 published sources
    • 25 with study appraisals
    • 25 linked conclusions
    • Complete profile
    Evidence and record details

    Evidence integrity map

    Human 2Preclinical 21Durable IDs 25Open signals 3
    Publication state
    Published profile
    Verified source records
    25 source records verified
    Chemistry record
    Chemistry record on file
    Regulatory entries
    2 published regulatory entries
    Research questions
    24 open research questions
    Evidence review date
    No documented human review recorded

    Source verification checks records; it does not itself approve scientific conclusions.

  • Vasopressin analog

    Desmopressin

    Peptide analog

    Developing

    Desmopressin is a synthetic analog of arginine vasopressin modified by deamination at position 1 and D-arginine at position 8. It preferentially activates renal V2 receptors, increasing collecting-duct water reabsorption through aquaporin-2 trafficking; V2-mediated endothelial release of von Willebrand factor and factor VIII underlies selected haemostatic uses. Clinical effects and risks differ materially by indication, dose, route, formulation, renal function, fluid intake, age, and concomitant medicines.

    • 26 published sources
    • 25 with study appraisals
    • no linked conclusions
    Evidence and record details

    Evidence integrity map

    Human 1Preclinical 0Durable IDs 7Open signals 2
    Publication state
    Published profile
    Verified source records
    26 source records verified
    Chemistry record
    Chemistry record on file
    Regulatory entries
    2 published regulatory entries
    Research questions
    No open questions documented
    Evidence review date
    No documented human review recorded

    Source verification checks records; it does not itself approve scientific conclusions.

  • Mitochondria-targeting peptide

    Elamipretide

    Synthetic peptide

    Evidence published; synthesis pending

    Mitochondria-targeting aromatic-cationic tetrapeptide that interacts with cardiolipin; evidence is separated by disease and endpoint.

    • 26 published sources
    • 25 with study appraisals
    • no linked conclusions
    Evidence and record details

    Evidence integrity map

    Human 0Preclinical 0Durable IDs 4Open signals 2
    Publication state
    Published profile
    Verified source records
    26 source records verified
    Chemistry record
    Chemistry record on file
    Regulatory entries
    2 published regulatory entries
    Research questions
    No open questions documented
    Evidence review date
    No documented human review recorded

    Source verification checks records; it does not itself approve scientific conclusions.

  • Synthetic tetrapeptide bioregulator

    Epitalon

    Emerging

    Epitalon (also transliterated Epithalon) is the tetrapeptide Ala-Glu-Asp-Gly associated with Russian peptide-bioregulator research. Proposed effects include modulation of gene expression, circadian biology, oxidative stress, and telomerase-related pathways, but mechanisms and clinical relevance remain uncertain.

    • 25 published sources
    • 25 with study appraisals
    • 25 linked conclusions
    • Complete profile
    Evidence and record details

    Evidence integrity map

    Human 1Preclinical 14Durable IDs 25Open signals 3
    Publication state
    Published profile
    Verified source records
    25 source records verified
    Chemistry record
    Chemistry record on file
    Regulatory entries
    2 published regulatory entries
    Research questions
    22 open research questions
    Evidence review date
    No documented human review recorded

    Source verification checks records; it does not itself approve scientific conclusions.

  • Endogenous copper-binding peptide complex

    GHK-Cu

    Peptide conjugate

    Emerging

    GHK-Cu is the copper(II) complex of the endogenous tripeptide glycyl-L-histidyl-L-lysine. It binds copper and has been studied in copper handling, extracellular-matrix remodeling, fibroblast activity, inflammatory signaling, antioxidant responses, and wound repair. Effects are formulation-, concentration-, route-, and model-dependent.

    • 25 published sources
    • 25 with study appraisals
    • 25 linked conclusions
    • Documented human review
    Evidence and record details

    Evidence integrity map

    Human 0Preclinical 8Durable IDs 24Open signals 3
    Publication state
    Published profile
    Verified source records
    25 source records verified
    Chemistry record
    Chemistry record on file
    Regulatory entries
    No published regulatory entry on file
    Research questions
    22 open research questions
    Evidence review date
    Documented human review recorded Sep 8, 2026

    Source verification checks records; it does not itself approve scientific conclusions.

  • Growth hormone secretagogue peptide

    GHRP-2

    Synthetic peptide

    Emerging

    Synthetic growth-hormone secretagogue and ghrelin-receptor agonist studied in endocrine challenge testing.

    • 26 published sources
    • 22 with study appraisals
    • no linked conclusions
    Evidence and record details

    Evidence integrity map

    Human 0Preclinical 0Durable IDs 5Open signals 1
    Publication state
    Published profile
    Verified source records
    26 source records verified
    Chemistry record
    Chemistry record on file
    Regulatory entries
    2 published regulatory entries
    Research questions
    No open questions documented
    Evidence review date
    No documented human review recorded

    Source verification checks records; it does not itself approve scientific conclusions.

  • Growth hormone secretagogue peptide

    GHRP-6

    Synthetic peptide

    Emerging

    Synthetic growth-hormone secretagogue and ghrelin-receptor agonist studied in endocrine and metabolic research.

    • 26 published sources
    • 25 with study appraisals
    • no linked conclusions
    Evidence and record details

    Evidence integrity map

    Human 0Preclinical 0Durable IDs 4Open signals 3
    Publication state
    Published profile
    Verified source records
    26 source records verified
    Chemistry record
    Chemistry record on file
    Regulatory entries
    2 published regulatory entries
    Research questions
    No open questions documented
    Evidence review date
    No documented human review recorded

    Source verification checks records; it does not itself approve scientific conclusions.

  • Growth hormone secretagogue peptide

    Hexarelin

    Synthetic peptide

    Emerging

    Synthetic hexapeptide growth-hormone secretagogue acting principally through the ghrelin receptor.

    • 27 published sources
    • 25 with study appraisals
    • no linked conclusions
    Evidence and record details

    Evidence integrity map

    Human 0Preclinical 0Durable IDs 5Open signals 1
    Publication state
    Published profile
    Verified source records
    27 source records verified
    Chemistry record
    Chemistry record on file
    Regulatory entries
    2 published regulatory entries
    Research questions
    No open questions documented
    Evidence review date
    No documented human review recorded

    Source verification checks records; it does not itself approve scientific conclusions.

  • Glycoprotein hormone / peptide-adjacent biologic

    Human chorionic gonadotropin (hCG)

    Protein or biologic

    Developing

    Placental heterodimeric glycoprotein hormone and LH/CG-receptor agonist; endogenous physiology, diagnostic measurement, authorized products, and nonmedical use are treated separately.

    • 25 published sources
    • 25 with study appraisals
    • no linked conclusions
    Evidence and record details

    Evidence integrity map

    Human 1Preclinical 0Durable IDs 1Open signals 1
    Publication state
    Published profile
    Verified source records
    25 source records verified
    Chemistry record
    Chemistry record on file
    Regulatory entries
    2 published regulatory entries
    Research questions
    No open questions documented
    Evidence review date
    No documented human review recorded

    Source verification checks records; it does not itself approve scientific conclusions.

  • Growth-hormone secretagogue

    Ipamorelin

    Developing

    Ipamorelin is a synthetic pentapeptide growth-hormone secretagogue that activates the ghrelin receptor (GHSR1a). It was designed to stimulate pulsatile growth-hormone release with less ACTH or cortisol stimulation than some earlier secretagogues.

    • 25 published sources
    • 25 with study appraisals
    • 25 linked conclusions
    • Complete profile
    Evidence and record details

    Evidence integrity map

    Human 3Preclinical 14Durable IDs 25Open signals 3
    Publication state
    Published profile
    Verified source records
    25 source records verified
    Chemistry record
    Chemistry record on file
    Regulatory entries
    2 published regulatory entries
    Research questions
    24 open research questions
    Evidence review date
    No documented human review recorded

    Source verification checks records; it does not itself approve scientific conclusions.

  • Kisspeptin fragment

    Kisspeptin-10

    Peptide fragment

    Emerging

    Bioactive C-terminal kisspeptin fragment that activates KISS1R and hypothalamic-pituitary-gonadal signaling.

    • 29 published sources
    • 25 with study appraisals
    • no linked conclusions
    Evidence and record details

    Evidence integrity map

    Human 0Preclinical 0Durable IDs 7Open signals 1
    Publication state
    Published profile
    Verified source records
    29 source records verified
    Chemistry record
    Chemistry record on file
    Regulatory entries
    2 published regulatory entries
    Research questions
    No open questions documented
    Evidence review date
    No documented human review recorded

    Source verification checks records; it does not itself approve scientific conclusions.

  • Alpha-MSH-derived tripeptide

    KPV

    Emerging

    KPV is the C-terminal tripeptide Lys-Pro-Val of alpha-melanocyte-stimulating hormone. Preclinical studies associate KPV and related analogs with anti-inflammatory and antimicrobial effects, including modulation of NF-kB-linked signaling and epithelial inflammatory responses.

    • 25 published sources
    • 25 with study appraisals
    • 25 linked conclusions
    • Complete profile
    Evidence and record details

    Evidence integrity map

    Human 0Preclinical 19Durable IDs 30Open signals 3
    Publication state
    Published profile
    Verified source records
    25 source records verified
    Chemistry record
    Chemistry record on file
    Regulatory entries
    2 published regulatory entries
    Research questions
    24 open research questions
    Evidence review date
    No documented human review recorded

    Source verification checks records; it does not itself approve scientific conclusions.

  • Somatostatin analog

    Lanreotide

    Peptide analog

    Developing

    Lanreotide is a synthetic cyclic octapeptide somatostatin analog with high affinity particularly for somatostatin receptor subtypes 2 and 5. Receptor activation suppresses growth-hormone secretion and multiple gastroenteropancreatic hormones and can exert antiproliferative effects in selected somatostatin-receptor-expressing neuroendocrine tumors. Depot and Autogel formulations provide prolonged exposure; approved indications and administration requirements vary by product and jurisdiction.

    • 25 published sources
    • 24 with study appraisals
    • no linked conclusions
    Evidence and record details

    Evidence integrity map

    Human 1Preclinical 0Durable IDs 7Open signals 1
    Publication state
    Published profile
    Verified source records
    25 source records verified
    Chemistry record
    Chemistry record on file
    Regulatory entries
    2 published regulatory entries
    Research questions
    No open questions documented
    Evidence review date
    No documented human review recorded

    Source verification checks records; it does not itself approve scientific conclusions.

How the public directory relates to the 501-record Master Registry

master registry transparency

501 master records, with governance status shown explicitly

WPF-MASTER-REGISTRY-TRANSPARENCY-1.0
501
Master records
467
Governed records
34
Review-deferred
458
Eligible for literature search
9
Governed comparators

The master registry has 467 governed identities from 501 records. 34 remain review-gated. Nine governed records are scientific comparators, leaving 458 peptide identities in the literature-search cohort (identities whose published literature WPF searches for; it does not refer to obtaining or buying any product). Database reconciliation is a separate step. The 51 profiles shown on this directory are a represented public-profile subset, not the size of the master registry. All 51 public profiles on this render reconcile to governed peptide identities in that registry; unknown, duplicate, deferred, or comparator identities fail closed instead of appearing publicly.

Which number counts what

  • 501 master records: the known registry of peptide and comparator identities (a catalog, never assumed complete).
  • 405 directory records in the search above: 51 full evidence profiles plus 354 source-only records (identities with published, verified sources but no full profile). The 23 result pages hold 18 records each and are counted from this same list.
  • 51 full evidence profiles: the profiles in the JSON export and the structured data on this page.
  • The observation form’s peptide selector uses a separate, more permissive list of identities that can be reported on; it is not the directory and not the evidence corpus.
Explore the full Master Registry →
What the profile status labels mean

Evidence, chemistry, and regulatory counts include only records that crossed the relevant public-publication gate. A zero means none published in that lane—not that nothing is known. “No governed record published” is a publication-state disclosure; internal or pending material may exist without appearing in public counts. Source verification, editorial publication, and accountable scientific appraisal are distinct states; a source count alone does not approve a scientific conclusion.

Recently updated public records

When each public profile record was last changed — not clinical or scientific activity.

Peptide Directory — World Peptide Foundation